(secondQuint)Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD.

 This will be a phase II, multi-centre, randomized, double-blind, placebo-controlled study designed to assess preliminary efficacy, safety and pharmacokinetics (PK) of 2-7 days continuous IV administration of sevuparin for the management of acute VOC in subjects with SCD.

 Adults and adolescents 12 years of age will be randomized to treatment with sevuparin or placebo (ratio 1:1).

.

 Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD@highlight

A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects with Sickle-Cell Disease (SCD).

